Ask your AI about this

Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:

Connect your AI · Plans and the 7-day free trial (card required)

Holdings, Q3 2026

Largest first. Common shares only.

Latest 13F holdings
#The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here.Filing
1SYRE
Spyre Therapeutics, Inc.
1.16M$103.3M37.8%-20.7%13F ↗
2ORKA
Oruka Therapeutics, Inc.
954,150$79.5M29.0%-39.1%13F ↗
3DMRA
Damora Therapeutics, Inc. · Comm Stk
2.05M$43.5M15.9%New13F ↗
4JBIO
Jade Biosciences, Inc.
1.81M$25.4M9.3%+14.6%13F ↗
5KRSA
Korsana Biosciences, Inc.
518,500$16.6M6.1%New13F ↗
6CBIO
Crescent Biopharma, Inc.
361,250$5.3M1.9%Unchanged13F ↗

Changes since Q2 2026

2 new, 1 added to, 2 trimmed, 2 exited, 1 unchanged. By estimated dollars.

New positions (2)

New positions
DMRA
Damora Therapeutics, Inc. · Comm Stk
2.05MNew$43.5M
KRSA
Korsana Biosciences, Inc.
518,500New$16.6M

Added to (1)

Added to
PositionSharesChangeEst. dollars
JBIO
Jade Biosciences, Inc.
1.81M+14.6%$3.2M

Trimmed (2)

Trimmed
ORKA
Oruka Therapeutics, Inc.
954,150-39.1%-$50.9M
SYRE
Spyre Therapeutics, Inc.
1.16M-20.7%-$27.0M

Exited (2)

Exited
Apogee Therapeutics Inc586,691Exited-$77.9M
Damora Therapeutics Inc2.05MExited-$53.2M

The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.

Compare two quarters

Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.

Reported value by quarter

Value and number of positions at the end of each quarter.

Loading…

Largest positions in earlier quarters

Pick a quarter to see what the fund's biggest positions were then.

Loading…

Ten largest positions

By value, Q3 2026.

$0$50.0M$100.0M$150.0MSYRE · Value: $103,329,999SYREORKA · Value: $79,471,154ORKADMRA · Value: $43,527,665DMRAJBIO · Value: $25,399,787JBIOKRSA · Value: $16,592,000KRSACBIO · Value: $5,270,638CBIO

Filings

13F filings
Filing
Q3 2026Nov 13, 202613F-HR6$273.6MCurrentSEC ↗
Q2 2026Aug 7, 202613F-HR6$451.6MCurrentSEC ↗
Q1 2026May 19, 202613F-HR/A (restatement)6$281.2MCurrentSEC ↗
Q1 2026May 13, 202613F-HR6$319.8MReplacedSEC ↗
Q4 2025Feb 12, 202613F-HR6$170.2M *CurrentSEC ↗

Most recent first, up to 80. An amendment can replace a report or add holdings to it. A * marks a report whose values we put in dollars; the adjusted figures are shown. All 13F filings

Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer